Novo Nordisk ADR

$19.00

Want a discount? Become a member by purchasing Annual Subscription!
SKU: NVO Category:

Description

Novo Nordisk A/S delivered a strong result and managed an all-around beat in the last quarter, boasting over 30% organic growth in both the top and bottom lines. The progress in the pipeline, including the SELECT readout and flow interim, has been exceptionally positive. The quarter witnessed an impressive milestone, with the company reaching 40 million people affected by diabetes. The acceleration in reaching an additional 4 million patients in the past year showcases the unprecedented pace driven by innovative solutions like Ozempic in diabetes. Financially, the company achieved a remarkable 33% sales growth and a 37% increase in operating profit at constant exchange rates. The robust performance extends to attractive cash flow generation and shareholder benefits through dividends and share buyback. Camilla Sylvest highlighted the impressive 33% sales growth, mainly driven by the North American operations. The growth is primarily attributed to obesity and GLP-1, with Ozempic being a significant driver. Challenges in insulin growth in international operations were addressed. The company further acquired Embark Laboratories and entered into a three-year research and development partnership to explore and create innovative pharmaceuticals for the treatment of obesity and associated comorbidities.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!